SCYX Q4 2023 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$6M+280.4% YoY

Gross Profit

-$9M-153.3% margin

Operating Income

-$23M-397.9% margin

Net Income

-$20M-337.9% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+229.2%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$557,000

Balance Sheet

Total Assets

$128M

Total Liabilities

$55M

Stockholders' Equity

$73M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+280.4%
Gross Profit	-$9M	$1M	-769.2%
Operating Income	-$23M	-$22M	-2.6%
Net Income	-$20M	-$14M	-35.7%

Revenue Segments

License and Service

$8M93%

Product

$576,0007%